Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on ACM, and more episode artwork

EPISODE · Apr 23, 2025 · 17 MIN

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on ACM, and more

from BiotechTV - News · host BiotechTV

He describes the clinical data in FA cardiomyopathy that was announced this month, and explains how the company is preparing to begin a clinical trial for accelerated approval by early 2026. Plus, how we should expect more ACM data in 2025.

He describes the clinical data in FA cardiomyopathy that was announced this month, and explains how the company is preparing to begin a clinical trial for accelerated approval by early 2026. Plus, how we should expect more ACM data in 2025.

NOW PLAYING

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on ACM, and more

0:00 17:55

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 17 minutes long.

When was this BiotechTV - News episode published?

This episode was published on April 23, 2025.

What is this episode about?

He describes the clinical data in FA cardiomyopathy that was announced this month, and explains how the company is preparing to begin a clinical trial for accelerated approval by early 2026. Plus, how we should expect more ACM data in 2025.

Can I download this BiotechTV - News episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!